Plus more appointments in contract pharma in this week's column.
Ergomed, a British drug development services company, has appointed Rolf Stahel to its board as a non-executive Chairman. Stahel was also recently made non-executive Chairman of Midatech , a UK company which uses gold nanoparticles for drug delivery.
The pharmaceutical veteran was CEO of Shire between 1994 and 2003, a tenure during which he oversaw six mergers and acquisitions. Prior to this, he worked for 27 years at Wellcome, where he rose to Director of Group Marketing, covering R&D portfolio decisions. Stahel also sits on the advisory board of Imperial Business School at Imperial College, London.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Quintiles has opened the global Solution Design Studio at its campus in Research Triangle Park in North...
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the...